CardioDEC is a next-generation cardiotoxicity assessment platform developed by EngiTissue Design Co., Ltd., a biotechnology company originating from Osaka University, Japan. Built on proprietary engineered heart tissue technologies, the platform combines human iPSC-derived cardiac tissues with dual excitation-contraction (DEC) recording to simultaneously measure electrophysiological and contractile responses in a physiologically relevant 3D environment. Compared with conventional engineered heart tissue assays, CardioDEC requires fewer cells, offers a simplified workflow, and reduces testing costs while maintaining high predictive accuracy. The platform enables comprehensive evaluation of cardiac safety, proarrhythmic risk, and drug efficacy, supporting faster, more reliable, and cost-effective drug development.